Bruker Announces U.S. Collaborations for the Clinical Validation of Rapid, Highly Specific & Low-Cost Microbial Identificatio...
18 May 2009 - 9:05PM
Business Wire
At the 109th General Meeting of the American Society for
Microbiology, Bruker Daltonics announced collaborations in the
United States for the clinical validation of its MALDI
Biotyper workflow for microorganism identification. The
MALDI Biotyper has recently obtained the IVD-CE Mark, and is
currently for Research Use Only (RUO) outside of the European
Union.
The MALDI Biotyper is a rapid, mass spectrometry based
platform for identifying bacteria, yeasts and fungi. A
high-quality, well-curated database with entries from over 3,000
strains cover approximately 2,000 well-characterized microbial
species. Starting from a cultured colony, the identification is
performed by matching the measured protein fingerprint against the
proprietary MALDI Biotyper database. Including the database
search, the automatic identification is performed in minutes,
multiple colonies can be spotted on a single target, and about
30-60 identifications an hour can be performed for high throughput.
The MALDI Biotyper specificity of identification is very
high and comparable to DNA sequencing, false positive rates are
near zero, mass spectrometry experience is not required and the
consumables cost per sample is very low.
In Europe, Bruker has installed over 40 MALDI Biotyper
instruments in routine laboratories for clinical microbiology, and
the MALDI Biotyper is rapidly becoming a new standard for
robust, rapid microbial identification. Recently, in the United
States several collaborations have been initiated to validate the
MALDI Biotyper for clinical usage. The Microbiology Service
of the NIH Clinical Center in Bethesda, MD has performed extensive
studies using the MALDI Biotyper for identification of
yeasts and bacteria. Their tests have shown advantages in cost,
speed, and accuracy compared with conventional biochemical testing
and gene sequencing, methods routinely used in their lab. The
collaboration with the NIH group is currently focused on expanding
the database for identification of mycobacteria, nocardia and
filamentous yeasts.
In addition, larger scale clinical research studies are also
underway at the microbiology departments of two major U.S. medical
school hospitals, and results from those studies are expected in
2009.
ABOUT BRUKER DALTONICS
For more information about Bruker Daltonics and Bruker
Corporation (NASDAQ: BRKR), please visit www.bdal.com and
www.bruker.com.
Photos/Multimedia�Gallery Available:
http://www.businesswire.com/cgi-bin/mmg.cgi?eid=5967247&lang=en
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024